RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 BMS-986001 is Effective Treatment for HIV-1-Infected Subjects
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 16
OP 17
DO 10.1177/155989771428009
UL http://mdc.sagepub.com/content/14/28/16.abstract
AB BMS-986001 is a novel nucleoside analog reverse-transcriptase inhibitor that, in higher doses, demonstrated comparable efficacy to tenofovir in treatment-naïve HIV-1-infected subjects. This article presents the results of this phase 2b randomized dose trial (active controlled, blinded to BMS-986001) with worldwide recruitment.